Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed
Cash returned and share count

No buyback or stock pay figures in its 10-K data yet

XBRL, 10-K

Where the cash came from and where it went

FY2026, from the cash flow statement in the 10-K, added up

Operating cash flowCash on hand usedCapital spendingAcquisitionsBuybacksOther, net Operating cash flow: $293.2M Operating cash flow $293.2M Cash on hand used: $61.3M Cash on hand used $61.3M Capital spending: $32.8M Capital spending $32.8M Acquisitions: $60.2M Acquisitions $60.2M Buybacks: $175.0M Buybacks $175.0M Other, net: $86.6M Other, net $86.6M

Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.

Where the operating cash went, year by year

FY2017 to FY2026 · cash flow statements, 10-K XBRL

10 years
Operating cash, added up $1.9B 10 fiscal years, FY2017 to FY2026
Reinvested 86% capital spending and acquisitions, as a share of that cash
Returned to owners 48% buybacks and dividends, as a share of that cash
Debt repaid $450.3M gross repayments added up; debt that was refinanced counts each time
Fiscal yearOperating cashCapital spendingAcquisitionsBuybacksDebt repaid
Mar 28, 2026 $293.2M $32.8M$60.2M$175.0M-
Mar 29, 2025 $181.7M $39.3M$150.9M$225.0M$4.7M
Mar 30, 2024 $181.8M $38.1M$243.9M-$12.2M
Apr 1, 2023 $273.1M $191.3M$2.9M$75.0M$9.6M
Apr 2, 2022 $172.3M $96.5M$2.5M-$17.5M
Apr 3, 2021 $108.8M $37.0M$434.8M-$21.9M
Mar 28, 2020 $158.2M $48.8M-$175.0M$13.1M
Mar 30, 2019 $159.3M $119.0M-$160.0M$266.9M
Mar 31, 2018 $220.3M $74.8M-$100.0M$61.7M
Apr 1, 2017 $159.7M $76.1M--$42.7M
Added up$1.9B $753.7M
39% of operating cash
$895.1M
47% of operating cash
$910.0M
48% of operating cash
$450.3M
24% of operating cash

Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.

Buybacks, dividends and share count

Year by year · XBRL, each 10-K

No buyback or share count data in the 10-K XBRL.

Buybacks month by month, and what is left to buy

Share buybacks · 10-Q, Part II Item 2, latest 4 quarters

“In April 2025, our Board approved a three-year share repurchase program authorizing the repurchase of up to $500.0 million of Haemonetics common stock, based on market conditions, through April 2028.”

10-Q, Part II Item 2

“As of December 27, 2025, the total remaining authorization for repurchases of our common stock under the share repurchase program was $425.0 million.”

10-Q, Part II Item 2
MonthShares boughtAverage price
Sep 2025 316,993 $47.32
Aug 2025 1,113,586 $53.88

Shares and average price are the numbers in the 10-Q table, row by row; "shares × price" is our multiplication of the two. A row with a price of "-" is an accelerated repurchase paid up front, where the 10-Q does not give a price yet. A 10-Q that counts shares in millions gives a rounded number, shown as "about". Shares withheld for employees' taxes are not in this table. A month that no 10-Q table gives, or that this page could not read with confidence, is not shown.

What it paid for each share it bought back

Price paid · 10-K, statement of shareholders' equity

Cheapest year $74.84 fiscal year to Mar 29, 2025
Dearest year $75.23 fiscal year to Apr 1, 2023
Average over these years $74.94 $301.8M spent

What HAE paid on average for each share it bought back, each fiscal year: dollars spent divided by shares bought, both from the 10-K.

Fiscal year toShares boughtSpentAverage price
Mar 29, 2025 3.03M$226.8M $74.84
Apr 1, 2023 997K$75.0M $75.23

Shares and dollars from the statement of shareholders' equity (the cash flow line also counts shares withheld for taxes, so it is not used). Share counts filed before a stock split are put on today's count. A year where the 10-K does not tag both numbers is left out.

What the 10-Ks show for each CEO's years

Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table

Christopher A. Simon

FY2022 to FY2026 · 5 years in the table
Operating cash flow
$1.1B
Capital spending
$398.0M
Acquisitions
$460.3M
Buybacks
$475.0M
Stock-based pay
$141.7M
Diluted shares since FY2021
-7.7%
Revenue since FY2021
+53%
Debt since FY2021
+$532.2M
CEO pay (reported)
$53.7M
The proxy that names the CEO

Sources

The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.

Also

CEO pay: what the CEO was paid over the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next:CEO pay
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.